key: cord-1050009-6dq6gm27
authors: Johnson, Betcy Susan; Laloraya, Malini
title: Cytokine Storm in COVID-19 patients transforms to a Cytokine Super Cyclone in patients with risk factors
date: 2020-07-01
journal: Cytokine Growth Factor Rev
DOI: 10.1016/j.cytogfr.2020.06.014
sha: 98958f83f31a8bb0a8ace9d10b4819da94e9c7cc
doc_id: 1050009
cord_uid: 6dq6gm27

The seventh human coronavirus SARS-CoV2 belongs to the cluster of extremely pathogenic coronaviruses like SARS-CoV and MERS-CoV, which are established to cause lower respiratory tract infection. The viral infection can be fatal as the disease advances to pneumonia followed by acute respiratory distress syndrome (ARDS). Increasingly higher cytokine concentration on account of over-stimulated immune response against the virus, or the ‘cytokine storm’, is the reason behind the manifestation of lethal clinical symptoms. In this article, we discuss the immune pathogenesis of cytokine storm and its relation with SARS-CoV2/COVID-19 risk factors. People with underlying risk factors are more susceptible to fatal complications of COVID-19 infection leading to poor clinical outcome. The increased pro-inflammatory immune status in patients with risk factors (diabetes, hypertension, cardiovascular disease, COPD) exacerbates the Cytokine-storm of COVID-19 to a Cytokine Super Cyclone. We also overviewed antiviral immune response provided by BCG vaccine involving the IL-1β, IL-6 and TNF-α secretion via ‘trained monocytes’, which confers early protection against SARS-CoV2.

. Viral entry into the host results in activation of innate immune mechanism together with the synthesis and secretion of inflammatory mediators. Interaction of specific viral components with pattern recognition receptors of the host immune system activates cellular signalling pathways that culminate in the production of various cytokines. These cytokines elicit host response like extravasation of leukocytes and activation, proliferation and cell differentiation of adaptive and innate immune system (7, 8) . Interleukin (IL)-1α/β, IL-18 and IL-6, tumor necrosis factor (TNF)-α, Interferon (IFN)-α/β, Transforming growth factor(TGF)-β are the major cytokines while CCL-2/monocyte chemoattractant protein (MCP)-1, MCP-3, CCL-3/Macrophage Inflammatory Protein (MIP)-1α, CCL-5 (Chemokine (C-C motif) ligand 5)/RANTES (regulated on activation, normal T cell expressed and secreted) and IFN-γinducible protein-10 (IP-10)/CXCL10 (C-X-C motif chemokine 10) are the chemokines released during an influenza virus-induced infection (9, 10) . These cytokines exert host antiviral responses in different ways. IFN-α/β is a type 1 interferon that can inhibit viral replication thus inducing a potent antiviral state in the host (11) , while TNF-α triggers the immune cells localization at infection site and activation of caspases to promote apoptosis (12) . IL-1 is a pleiotropic cytokine, which enhances inflammatory cell infiltration by increasing membrane permeability through activation of mast cells and subsequent release of histamine, a vasodilator (13) . IL-6 mediates monocyte differentiation to macrophages and enhances mononuclear cell infiltration to the inflammation loci (14) . Moreover, synergistically IL-6 and TGF-β induces maturation of naive helper T cells (CD4+) to T Helper 17 (TH17) cells which are potential effectors against pathogens. Interestingly, IL-6 also hinders the Treg expansion by TGF-β (15, 16) . Enhancement of type 1 immunity, activation of natural killer T cells (NKT) cells thus forming an early line of defence against viral infection are some of the biological actions of IL-18 during viral infection (17, 18) .

Although these cytokines are released either as host protection or response against viral entry, exacerbated cytokine release can adversely affect the host by overreacting to its own system/ organs named as 'cytokine storm 'and was observed in both SARS and MERS infection resulting in the associated severe complications and multiple organ failure (19) . Studies have established that similar hypercytokinemia/cytokine storm is also taking part in SARS-CoV2/COVID-19 infection. In this review we highlight the pathology and pathogenesis of J o u r n a l P r e -p r o o f MERS CoV, SARS CoV and SARS CoV2, with main focus into the role of cytokines in pathology and its relation with co-morbidities of COVID-19 infection (20) .

Epidemic outbreak in 2002-2003 by SARS-CoV had a case fatality ratio of 14% to 15%, which was higher in older age group (greater than 50%) and less than 1% in younger age group SARS CoV entry to the cells is mediated by ACE2 (Angiotensin converting enzyme 2) receptor which is extremely expressed in lung, kidney, heart, liver and tongue. Viral Spike protein binds to the receptor, followed by viral fusion with the cell membrane, which involves priming of S protein by proteases of the cell surface and finally ends up in entry and replication of the virus inside the cell (24) . It has been shown that ACE2 has protective role in ALI (25) . ACE2 play a key role in renin-angiotensin system (RAS) that maintains blood pressure and water electrolyte balance. Decreased expression of ACE2 negatively affects RAS system followed by increased microvascular permeability and inflammation (26) . ACE2 expression has also been found to be down regulated by SARS CoV infections, which further augments the intensity of lung injury (27) . Moreover, increased viral load, excessive immune cell infiltration and increased innate immune response by pro-inflammatory mediators also lead to widespread lung injury in SARS, suggesting both cytokine storm and direct cytopathogenic effect of the virus cause the physiological decompensation observed in SARS CoV infection (28) .

Profiling of systemic cytokine levels in individuals suffering from SARS-CoV disease showed elevated concentrations of T Helper 1 (TH1) cytokines like IFN-γ, IL-2 and IL-12.

Additionally, cytokines that promote inflammation like IL-6, IL-1, MCP-1, IP-10, CXCL9/MIG (monokine induced by gamma interferon), IL-18, TGF-β and IL-8 were also

increased (29) (30) (31) (32) (33) . Interestingly, SARS patients showed no change in blood IL-10 and IL-4 J o u r n a l P r e -p r o o f levels (33) . Increased amount of MIG, MCP-1, IP-10, IL-6, IL-8 and IL-18 in blood correlated with disease severity in SARS patients (30, 31 Interstitial infiltrates were observed in chest radiography of MERS-CoV infected individuals.

Laboratory investigation showed increased concentration of LDH and aspartate aminotransferase (AST), low eosinophil and platelet count and decreased albumin level (38) . Another major cytokine that mediate organ damage in cytokine storm is IL-6. Excessive secretion of IL-6 results in activation of coagulation pathway conversion of naive T cells, increase in vascular permeability and reduced cardiac function contribute to the increased disease severity (62, 63) . SARS patients also showed increased levels of IL-6 which correlated with disease progression (30) . Increased levels of Th17 CD4 T cells seen in COVID-19 patients can be explained by high levels of IL-6, which is implicated in T Helper 17 (TH17) cells development (16, 64) . Interestingly, spike protein of SARS COV induced activation of NF-κB signalling resulting in IL-6 and TNF-α secretion in murine macrophages (65) . Later in another study reported that inhibiting NF-κB signalling was demonstrated with decreased IL-6 levels and increased animal survival in SARS (66) . These studies implicate IL-6 to be a key contributor to the patho-physiology of the cytokine-storm seen in both the SARS CoV infections. One of the proposed mechanisms for decreased T cells in COVID-19 infection could be mediated by increased levels of IL-6 and increased interaction between Fas and its ligand.

Moreover, an increased number of lymphocytes were observed in patients SARS CoV2 infection when treated with tocilizumab, the IL-6 receptor antagonist (67, 68) . Yet more studies are required for speculating the exact mechanism of SARS Cov2 induced lymphopenia, and 

Although the occurrence of COPD in COVID-19 patients was reported as 3.2% (74), the rate of disease severity and the mortality rate was markedly high with 60% and 63% respectively 

The death rate of COVID-19 patients with CVD was 10.5% (92) . The and observational studies, it has been shown that BCG vaccination could reduce the neonatal as well as childhood death rate (116, 117) . Retrospective cross-sectional study conducted in sub-Saharan African children of below 5 years demonstrated a positive association of BCG vaccination and lower threat of malaria (118) . Additionally, epidemiological studies have also established the protective role of BCG against respiratory tract infections in children which are predominantly virus-mediated (119, 120) . Vaccination with BCG enhanced IFN-γ and IL-10 level, thus providing immunity against respiratory tract infection even in elderly age group (121) . This is because, BCG also provides some non-specific immune assistance like immunity against pathogens other than mycobacteria like virus and parasites and reduces the occurrence of allergy. This is attained through a mechanism termed as trained immunity which is the immunological recall of the innate immune system via epigenetic reprogramming (122) . Innate immune cells like monocytes, NK cells and macrophages undergo epigenetic modifications of histones that include methylation and acetylation, enhances gene expression of IL-6, TNF-α and IL-1β upon BCG vaccination. Thus, the trained phenotype of innate immune cells results an increase in secretion of pro-inflammatory cytokines on exposure to non-specific pathogen, enhancing host protection (123, 124) . It has been experimentally shown that healthy subjects immunized with BCG show increased production of TNF-α and IL-1β in response to bacterial and non-bacterial stimulants. Increased H3K4me3 (trimethylation of histone H3 at lysine 4) exposed promoter regions of these pro-inflammatory cytokines leading to their increased expression (125) . In another study BCG vaccination reduced viremia in experimental human yellow fever virus infection model by inducing trained immunity by epigenetic modification of monocytes, resulting in increased production of IL-1β (126) . Moreover, BCG could enhance heterologous TH1/TH17 responses by inducing the long-lasting release of IL-22, IFN-γ, and IL-17 thereby attaining non-specific immune response to infections (127) . In line with this, several in vivo studies in murine models were also reported. BCG immunized mice expressed antimicrobial peptides and bestowed protection against malarial parasitemia (128) .

Additionally, prior BCG vaccination in influenza virus challenged mice were found to have considerable protection via secretion of antibody or activation of cell-mediated immunity (129) . A study conducted in mice model, to understand the effect of BCG against various viral infections like herpes simplex type 1, influenza A2 and encephalomyocarditis viruses showed increased resistance of BCG immunised mice against these viruses compared to control mice J o u r n a l P r e -p r o o f (130) . Specifically, BCG vaccinated newborn mice were shown to be more resistant against

Herpes Simplex Type 2 Infection (131). Based on these observations it has been proposed that BCG vaccine has the potential to act as a protective agent against SARS CoV2, as it provides antiviral immunity (132) . SARS-CoV2 virus enhances the generation of IL-6, IFN-γ, TNF-α and IL-1β in mild to severely infected patients (48) . As discussed earlier, the trained immunity of BCG vaccine involves the release of these cytokines, thus providing an antiviral state and earlier protection against SARS-CoV2 (Figure 3 ). Ozdemir Malini Laloraya: Conceptualization, Writing-Reviewing and Editing, Supervision.

None.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

The molecular biology of coronaviruses

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses2020. 2020. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Coronavirus disease 2019 (COVID19) outbreak: Could pigs be vectors for human infections

COVID-19, SARS and MERS: are they closely related?

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

COVID-19: what has been learned and to be learned about the novel coronavirus disease

Cytokine production and signaling pathways in respiratory virus infection

Molecular pathways in virus-induced cytokine production. Microbiol

Susceptibility of mononuclear phagocytes to influenza A virus infection and possible role in the antiviral response

Influenza virus neuraminidase activates latent transforming growth factor beta

Antiviral actions of interferons

TNF-A¦ induces two distinct caspase-8 activation pathways

Interleukin 1 releases histamine from human basophils and mast cells in vitro

IL-6 switches the differentiation of monocytes from dendritic cells to macrophages

Physiological effects of modulating the interleukin-6 axis

IL: regulator of Treg/Th17 balance

Unique action of interleukin-18 on T cells and other immune cells

Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokinereceptor system

Severe acute respiratory syndrome

Lung pathology of fatal severe acute respiratory syndrome

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area

Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitorsÇölessons from available evidence and insights into COVID-19

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Angiotensin-converting enzyme 2 in lung diseases

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARSÇÉCoV, MERSÇÉCoV, and 2019ÇÉnCoV

Early enhanced expression of interferoninducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome

Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome

An interferonrelated cytokine storm in SARS patients

Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS

Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses

Dysregulated type I interferon and inflammatory monocytemacrophage responses cause lethal pneumonia in SARS-CoV-infected mice

Assessing the pandemic potential of MERS-CoV

Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a singlecenter experience in Saudi Arabia

From SARS to MERS, thrusting coronaviruses into the spotlight

Differential expression of the Middle East respiratory syndrome coronavirus receptor in the upper respiratory tracts of humans and dromedary camels

Histopathology of Middle East respiratory syndrome coronovirus (MERSÇÉCoV) infectionÇôclinicopathological and ultrastructural study

MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2

Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways

Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection

MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile

Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Structure analysis of the receptor binding of 2019-nCoV

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

Dysregulation of immune response in patients with COVID-19 in Wuhan

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells

Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice

Regulation of pulmonary fibrosis by chemokine receptor CXCR3

Host response-based screening to identify undiagnosed cases of COVID-19 and expand testing capacity

Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Immunotherapeutic implications of IL-6 blockade for cytokine storm

2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway

Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome

Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. medRxiv

SARS-CoV-2 activates lung epithelia cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients by single-cell sequencing

Type 1 interferons as a potential treatment against COVID-19

Interferon alpha 2b Treatment for COVID-19

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

2020. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis

Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview

Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease

The cytokine network in chronic obstructive pulmonary disease

Markers of disease severity in chronic obstructive pulmonary disease

Systemic manifestations and comorbidities of COPD

Multiple Circulating Cytokines Are Coelevated in Chronic Obstructive Pulmonary Disease

COVID-19: A drug repurposing and biomarker identification by using comprehensive gene-disease associations through protein-protein interaction network analysis

ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19

Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis

Immune Mechanisms in Arterial Hypertension

Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?

An imbalance in serum concentrations of inflammatory and anti-inflammatory cytokines in hypertension

Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Hypertension and diabetes delay the viral clearance in COVID-19 patients

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Atherosclerosis: process, indicators, risk factors and new hopes

Cytokines and cardiovascular disease

Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation

Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy

Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

Type 2 Diabetes Mellitus and Altered Immune System Leading to Susceptibility to Pathogens, Especially Mycobacterium tuberculosis

Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis

Role of inflammation in diabetic complications

Is type II diabetes mellitus a disease of the innate immune system? Diabetologia

Inflammatory process in type 2 diabetes: The role of cytokines

Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation

Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy

Role of immune system in type 1 diabetes mellitus pathogenesis

Role of Pro-Inflammatory Cytokines and Biochemical Markers in the Pathogenesis of Type 1 Diabetes: Correlation with Age and Glycemic Condition in Diabetic Human Subjects

Proteins of TNF-α and IL6 Pathways Are Elevated in Serum of Type-1 Diabetes Patients with Microalbuminuria

Evaluation of pro-inflammatory and anti-inflammatory cytokines in type 1 diabetes mellitus

Signaling and Favor Type 1 Diabetes Development in Nonobese Diabetic Mice. Front Immunol

COVID-19 and diabetes: Knowledge in progress

Altered cytokine network in gestational diabetes mellitus affects maternal insulin and placental-fetal development

Circulating pro-and anti-inflammatory cytokines in Polish women with gestational diabetes

Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?

Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review

BCG vaccination is associated with reduced malaria prevalence in children under the age of 5 years in sub-Saharan Africa

Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study

Acute lower respiratory infection among Bacille Calmette-Guérin (BCG)-vaccinated children

The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly

BCG-induced protection: effects on innate immune memory

BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design

BCG-induced trained immunity: can it offer protection against COVID-19?

Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes

BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity

Longlasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity

Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination

Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guérin

Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guérin)

Could BCG be used to protect against COVID-19?

Is BCG vaccination affecting the spread and severity of COVID-19?

Association of Bacille Calmette-Gurin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19

Adjusted Mortality Rates in Level 4 European countries

The BCG World Atlas: a database of global BCG vaccination policies and practices

Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study

Significantly improved COVID-19 outcomes in countries with higher BCG vaccination coverage: A multivariable analysis

BCG vaccines may not reduce COVID-19 mortality rates. medRxiv

Does TB vaccination reduce COVID-19 infection?: No evidence from a regression discontinuity analysis. No Evidence from a Regression Discontinuity Analysis

Completed her post-graduation degree on Medical Biochemistry in 2013 from Calicut University, India. She is currently pursuing PhD at Female Reproduction and Metabolic Syndrome Laboratory, Rajiv Gandhi Centre for Biotechnology